See inside every stock. Pro
S&P 5007,624▼ 0.52%Nasdaq25,955▼ 0.21%Dow Jones52,215▼ 1.23%Nasdaq 10028,958▼ 0.00%VIX19.45▲ 2.21%US Dollar101.75▲ 0.14%Gold spot4,012▼ 0.30%WTI103.27▲ 3.82%
← 302440 page
XStocksXray
Market X-Ray report · 23 October 2026

SK Bioscience Co Ltd (302440)

Korea Stock Exchange · Korea · prices in KRW · close of 23 Oct 2026

Key indicators

Last closeKRW 33,150.00
52-week range31,800.00 – 61,300.00
Return, 1 month / 3 months−7.3% / −1.5%
Return, 1 year / 3 years−32.7% / −43.7%
TrendBelow its 200-day average
RSI (14)34
Volatility (1 year)44.6%
Worst drawdown (1 year)-45.9%
Average daily value traded2,772.24M KRW
Dividend yield–

Market X-Ray price-based

50/ 100 · High confidence · ahead of 50% of stocks on this exchange
Trend38
Momentum44
Stability (higher is calmer)54
Liquidity71
Income–

Five-year price chart navy: price · brown: 200-day average

17,62087,060156,500225,940295,3802021-102023-012024-042025-072026-10

About the company

SK Bioscience is a South Korean biopharmaceutical company that develops and manufactures vaccines. Its work covers influenza vaccines grown in cell culture and other preventive vaccines, and it also provides contract manufacturing and fill-and-finish services for partners. The company serves public health programmes and pharmaceutical partners in Korea and abroad, and it is based in Seongnam, near Seoul.

The shares are listed on the Korea Stock Exchange in Korea under the code 302440, and the price on this page is in South Korean won (KRW). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

SK Bioscience Co Ltd (302440) trades on the Korea Stock Exchange in Korea. It last closed at KRW 33,150.00 on 23 October 2026.

Its price-based Market X-Ray is 50 out of 100 (a weak price profile), ranking 471 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price fell 32.7% and over the last three months it fell 1.5%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
SK Bioscience Co Ltd (302440)

The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange

Lens and metricValueScoreReading
Trend38 · WeakBelow its long-term averages and far from its highs.
Above 200-day average-19.4%
From 52-week high-44.8%
Momentum44 · WeakLagging most stocks on this exchange.
3-month return-1.5%
6-month return-24.9%
12-month return, skipping the last month-27.4%
Stability (higher is calmer)54 · FairTypical risk for this exchange.
Volatility, 1 year (lower is calmer)44.6%
Worst drawdown, 1 year (smaller is calmer)-45.9%
Liquidity71 · StrongTrades actively.
Average daily value traded2,772.24M KRW
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Liquidity: Trades actively.

Weak spots

  • Trend: Below its long-term averages and far from its highs.
  • Momentum: Lagging most stocks on this exchange.

Returns

1 week−8.7%
1 month−7.3%
3 months−1.5%
6 months−24.9%
1 year−32.7%
3 years−43.7%
5 years−85.3%

Signals

50-day / 200-day average36,806.00 / 41,131.50
Golden / death cross (60 days)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1,379.08

Technical summary

DailyStrongly bearish3 bullish · 1 neutral · 12 bearish
WeeklyStrongly bearish0 bullish · 1 neutral · 11 bearish
MonthlyStrongly bearish0 bullish · 1 neutral · 7 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 24 Oct 2026